Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Ciucci, Alessandra ^a   De Stefano, Ilaria ^a   Vellone, Valerio Gaetano ^a   Lisi, Lucia ^a   Bottoni, Carolina ^a   Scambia, Giovanni ^a   Zannoni, Gian Franco ^a   Gallo, Daniela ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPAMINE; PACLITAXEL; PLATINUM COMPLEX; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; POSTMENOPAUSE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; AGED; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CINNAMATES; FEMALE; HUMANS; IMMUNOPRECIPITATION; MIDDLE AGED; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; VERATRUM ALKALOIDS;

ERINACEIDAE;

EID: 84875530284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060145     Document Type: Article

References (40)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Cannistra SA, (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529.
3. McMillan R, Matsui W, (2012) Molecular pathways: the hedgehog signaling pathway in cancer. Clin Cancer Res 18: 4883-4888.
4. Teglund S, Toftgård R, (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805: 181-208.
5. Kar S, Deb M, Sengupta D, Shilpi A, Bhutia SK, et al. (2012) Intricacies of hedgehog signaling pathways: A perspective in tumorigenesis. Exp Cell Res 318: 1959-1972.
6. Ruiz i Altaba A, Mas C, Stecca B, (2007) The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 17: 438-447.
7. Stecca B, Ruiz I Altaba A, (2010) Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol 2: 84-95.
8. Gallo D, Ferlini C, Scambia G, (2010) The epithelial-mesenchymal transition and the estrogen-signaling in ovarian cancer. Curr Drug Targets 11: 474-481.
9. Incardonam JP, Gaffield W, Kapur RP, Roelink H, (1998) The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development 125: 3553-3562.
10. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, et al. (2000) Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406: 1005-1009.
11. Lauth M, Bergström A, Shimokawa T, Toftgård R, (2007) Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 104: 8455-8460.
12. Onishi H, Katano M, (2011) Hedgehog signaling pathway as a therapeutic target in various types of cancer. Cancer Sci 102: 1756-1760.
13. Rustin GJ, (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21: 187-193.
14. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, et al. (2004) Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96: 487-488.
15. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, et al. (2007) Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol14: 195-208.
16. De Stefano I, Zannoni GF, Prisco MG, Fagotti A, Tortorella L, et al. (2011) Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol 122: 573-579.
17. Gerber AN, Wilson CW, Li YJ, Chuang PT, (2006) The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting MyoD-mediated transcriptional activation. Oncogene 26: 1122-1136.
18. Marcotullio LD, Ferretti E, Greco A, De Smaele E, Po A, et al. (2006) Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itchdependent ubiquitination. Nat Cell Biol 8: 1415-1423.
19. ten Haaf A, Bektas N, von Serenyi S, Losen I, Arweiler EC, et al. (2009) Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer. Aug 25 9: 298.
20. Pizem J, Popovic M, Cör A, (2011) Expression of Gli1 and PARP1 in medulloblastoma: an immunohistochemical study of 65 cases. J Neurooncol 103: 459-467.
21. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, et al. (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115: 1234-1244.
22. Stecca B, Ruiz i Altaba A, (2009) A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J 28: 663-676.
23. Shi Y, Moura U, Opitz I, Soltermann A, Rehrauer H, et al. (2012) Role of hedgehog signaling in malignant pleural mesothelioma. Clin Cancer Res 18: 4646-4656.
24. Jabbar SA, Twentyman PR, Watson JV, (1989) The MTT assay underestimates the growth inhibitory effects of interferons. Br J Cancer 60: 523-528.
25. Sieuwerts AM, Klijn JG, Peters HA, Foekens JA, (1995) The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem 33: 813-823.
26. Wang P, Henning SM, Heber D, (2010) Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One 5: e10202 doi:10.1371/journal.pone.0010202.
27. Chen X, Horiuchi A, Kikuchi N, Osada R, Yoshida J, et al. (2007) Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer Sci 98: 68-76.
28. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, et al. (2008) Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 14: 7659-7666.
29. Liao X, Siu M K, Au CW, Wong ES, Chan H Y, et al. (2009) Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 30: 131-140.
30. Yang L, He J, Huang S, Zhang X, Bian Y, et al. (2009) Activation of hedgehog signaling is not a frequent event in ovarian cancers. Mol Cancer 8: 112.
31. Chen JK, Taipale J, Cooper MK, Beachy PA, (2002) Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 16: 2743-2748.
32. Schmid S, Zhang F, Zhang M, He B, Jablons D, et al. (2010) Interactions and dynamics of hedgehog and Wnt pathway activation levels in ovarian cancer cell lines. J Clin Oncol; 28 (suppl; abstr e15515).
33. Mozzetti S, Martinelli E, Raspaglio G, Prislei S, De Donato M, et al. (2012) Gli family transcription factors are drivers of patupilone resistance in ovarian cancer. Biochem Pharmacol pii: S0006-2952(12)00575-8.
34. Kudo K, Gavin E, Das S, Amable L, Shevde LA, et al. (2012) Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene doi: 10.1038/onc.2011.610.
35. Kandala PK, Srivastava SK, (2012) Diindolylmethane-mediated Gli1 Protein Suppression Induces Anoikis in Ovarian Cancer Cells in Vitro and Blocks Tumor Formation Ability in Vivo. J Biol Chem 287: 28745-28754.
36. Shaw A, Bushman W, (2007) Hedgehog signaling in the prostate. J Urol 177: 832-838.
37. Merchant AA, Matsui W, (2010) Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 16: 3130-3140.
38. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, et al. (2008) A paracrine requirement for hedgehog signalling in cancer. Nature 455: 406-410.
39. Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, et al. (2012) Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther 11: 1587-1597.
40. Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, et al. (2012) A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission. Clin Cancer Res 18: 6509-6518.